AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26568833 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels in patients with HFPEF
Number of subjects: 86
Study 26568833 — intervention group
Group type: EXPERIMENTAL
Intervention: Log copeptin
Number of subjects: 86
Study 26568833 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP correlation
Number of subjects: 86
Study 26568833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction assessment
Number of subjects: 86
Study 26568833 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite end point of all-cause mortality or HF hospitalisation
Number of subjects: 86
Study 26568832 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital heart disease (CHD) group
Number of subjects: 365
Study 26568832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligence assessment in CHD group
Number of subjects: 365
Study 26568832 — intervention group
Group type: EXPERIMENTAL
Intervention: Alertness assessment in CHD group
Number of subjects: 365
Study 26568832 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functions (EF) assessment in CHD group
Number of subjects: 365
Study 26568832 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory assessment in CHD group
Number of subjects: 365
Study 26568832 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 365
Study 26569533 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated depressive symptoms
Number of subjects: 89
Study 26569533 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous severity of depressive symptoms
Number of subjects: 89
Study 26571268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom treatment (subchronic)
Number of subjects: 0
Study 26571268 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of bee venom
Number of subjects: 0
Study 26571268 — intervention group
Group type: EXPERIMENTAL
Intervention: Apamin (blocker of SK channels)
Number of subjects: 0
Study 26571268 — intervention group
Group type: EXPERIMENTAL
Intervention: CyPPA (positive modulator of SK channels)
Number of subjects: 0
Study 26571268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom
Number of subjects: 0
Study 26571268 — intervention group
Group type: COMPARATOR
Intervention: Control (neuroleptic treatment and 6-hydroxydopamine injection)
Number of subjects: 0
Study 26571311 — intervention group
Group type: EXPERIMENTAL
Intervention: rSm14/GLA-SE vaccine (50 μg rSm14 with 10 μg GLA-SE, intramuscularly, three doses with 30-day intervals)
Number of subjects: 20
Study 26572233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 0
Study 26572233 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26572865 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous HIV testing followed by confidential care linkage
Number of subjects: 0
Study 26573078 — intervention group
Group type: EXPERIMENTAL
Intervention: DPYD*2A genotype-guided dosing (initial dose reduction of ≥ 50%)
Number of subjects: 2038
Study 26573078 — intervention group
Group type: EXPERIMENTAL
Intervention: DPYD*2A genotype-guided dosing
Number of subjects: 2038
Study 26573078 — intervention group
Group type: COMPARATOR
Intervention: Screening for DPYD*2A
Number of subjects: 2038
Study 26573139 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT/IGRT with 50 Gy in 2 Gy single fractions (5 fractions per week)
Number of subjects: 50
Study 26573139 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT/IGRT
Number of subjects: 50
Study 26573577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolim® stent
Number of subjects: 204
Study 26573686 — intervention group
Group type: EXPERIMENTAL
Intervention: Equimolar mixture of oxygen and nitrous oxide
Number of subjects: 0
Study 26573686 — intervention group
Group type: EXPERIMENTAL
Intervention: Other analgesic drugs
Number of subjects: 0
Study 26573827 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrinkage Estimator (SHE)
Number of subjects: 0
Study 26573827 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability Tree Estimator (PTE)
Number of subjects: 0
Study 26573827 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Likelihood Estimator (MLE)
Number of subjects: 0
Study 26574583 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (300 µg PM(2.5)/m(3))
Number of subjects: 18
Study 26574583 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 18
Study 26575422 — intervention group
Group type: EXPERIMENTAL
Intervention: AvidinOX-anchored biotinylated Cetuximab (bCet)
Number of subjects: 1
Study 26575422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-tumor injection of AvidinOX with low dose bCet
Number of subjects: 1
Study 26575452 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 0
Study 26576059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 383
Study 26576059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (15-35 mg/kg/day)
Number of subjects: 383
Study 26576059 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fetal hemoglobin responses to hydroxyurea
Number of subjects: 383
Study 26576546 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Met (158) allele
Number of subjects: 100
Study 26576546 — intervention group
Group type: COMPARATOR
Intervention: Val (158) /Val (158) homozygotes
Number of subjects: 100
Study 26576546 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Val (158) Met polymorphism
Number of subjects: 100
Study 26576744 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma cohorts (mild, moderate, severe)
Number of subjects: 188
Study 26576744 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma cohort
Number of subjects: 188
Study 26576744 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control questionnaire-7 (ACQ7) scores
Number of subjects: 188
Study 26576744 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum eosinophils
Number of subjects: 188
Study 26576744 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO and blood eosinophils
Number of subjects: 188
Study 26576744 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and biomarker characteristics in asthmatics
Number of subjects: 188
Study 26577301 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent iodine-125 seed implantation (PI)
Number of subjects: 2160
Study 26577301 — intervention group
Group type: COMPARATOR
Intervention: PI combined with external beam radiation therapy (PI + EBRT)
Number of subjects: 2160
Study 26577754 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG) implant
Number of subjects: 52
Study 26578201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital morphine use
Number of subjects: 2438
Study 26578401 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer Index (BCI) genomic classification
Number of subjects: 96
Study 26578401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test anxiety and decision conflict measures
Number of subjects: 96
Study 26578722 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (30 mg weekly) with Carboplatin (area under the curve 6) and Paclitaxel (200 mg/m²) every 3 weeks
Number of subjects: 45
Study 26578722 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus combined with Carboplatin and Paclitaxel
Number of subjects: 45
Study 26578731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion (HAI) with triplet chemotherapy (irinotecan 180 mg/m², oxaliplatin 85 mg/m², 5-fluorouracil 2800 mg/m²) and systemic cetuximab (500 mg/m²) every 14 days.
Number of subjects: 64
Study 26578731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion (HAI) with triplet chemotherapy and systemic cetuximab.
Number of subjects: 64
Study 26578849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 220 mg once daily
Number of subjects: 4374
Study 26578849 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 4374
Study 26579222 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing through N95-mask materials
Number of subjects: 20
Study 26579227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0
Study 26579524 — intervention group
Group type: EXPERIMENTAL
Intervention: Health at Every Size(®)-based intervention
Number of subjects: 30
Study 26579723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheehan Irritability Scale (SIS)
Number of subjects: 586
Study 26579723 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (inadequate response)
Number of subjects: 586
Study 26580449 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based randomized intervention trial designed to promote breast and cervical cancer screening
Number of subjects: 421
Study 26580449 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a partner
Number of subjects: 421
Study 26580449 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 421
Study 26580449 — intervention group
Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 421
Study 26580449 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher worry
Number of subjects: 421
Study 26580968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular prevention program in Sollentuna
Number of subjects: 56589
Study 26581135 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy intensity modulated radiation therapy with concurrent weekly intravenous cisplatinum (30 mg/m(2))
Number of subjects: 43
Study 26581137 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a prescribed dose of 48 Gy at the isocenter in 4 fractions
Number of subjects: 164
Study 26581381 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (sleeve gastrectomy, proximal RYGB, distal RYGB)
Number of subjects: 0
Study 26581381 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight and less-obese subjects (control)
Number of subjects: 0
Study 26581547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg once daily
Number of subjects: 27
Study 26582138 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based patient-provider communication (IPPC) service
Number of subjects: 17
Study 26582138 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison with other studies using CFIR
Number of subjects: 17
Study 26582161 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary leakage present
Number of subjects: 59
Study 26582161 — intervention group
Group type: COMPARATOR
Intervention: No papillary leakage
Number of subjects: 59
Study 26582161 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal IOP
Number of subjects: 59
Study 26582161 — intervention group
Group type: COMPARATOR
Intervention: Secondary glaucoma
Number of subjects: 59
Study 26582161 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary glaucoma with optic disc leakage
Number of subjects: 59
Study 26582805 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 183
Study 26582805 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) insulin therapy
Number of subjects: 183
Study 26582853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% ACB with 20 ml
Number of subjects: 40
Study 26582853 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1% ACB with varying volumes (5 ml, 10 ml, 15 ml, 20 ml)
Number of subjects: 40
Study 26582853 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% ACB
Number of subjects: 40
Study 26583301 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of relaxin over 48 hours
Number of subjects: 0
Study 26583301 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin
Number of subjects: 0
Study 26583503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition white light (WL)
Number of subjects: 0
Study 26583503 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging with magnification (NBI)
Number of subjects: 0
Study 26583503 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE)
Number of subjects: 0
Study 26583503 — intervention group
Group type: EXPERIMENTAL
Intervention: High degrees of histologic inflammation with WL
Number of subjects: 0
Study 26583503 — intervention group
Group type: EXPERIMENTAL
Intervention: High degrees of histologic inflammation with CE
Number of subjects: 0
Study 26583503 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 0
Study 26583503 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE) added to WL
Number of subjects: 0
Study 26583585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 118
Study 26583585 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 nonobese, nondiabetic subjects)
Number of subjects: 118
Study 26584600 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings of patients with advanced adenomas (exposed)
Number of subjects: 600
Study 26584600 — intervention group
Group type: COMPARATOR
Intervention: Siblings of subjects with normal findings (unexposed)
Number of subjects: 600
Study 26584601 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom score of 20
Number of subjects: 269
Study 26584601 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom score of 15
Number of subjects: 269
Study 26584601 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom score as a continuous variable
Number of subjects: 269
Study 26584601 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical remission defined as symptom score <20
Number of subjects: 269
Study 26584601 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic remission defined as absence of white exudates, moderate or severe rings, strictures, or combination of furrows and edema
Number of subjects: 269
Study 26584601 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic remission defined as peak count of <20 eosinophils/mm(2)
Number of subjects: 269
Study 26584760 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state EEG band power measures
Number of subjects: 42
Study 26584760 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest correlation of EEG band power measures
Number of subjects: 42
Study 26584787 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Global Assessment (SGA)
Number of subjects: 489
Study 26584787 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition Inflammation Score (MIS)
Number of subjects: 489
Study 26584787 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 489
Study 26584787 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney Disease Quality of Life Short Form 1.3
Number of subjects: 489
Study 26584787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-related tests (8 total)
Number of subjects: 489
Study 26585432 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for 21 days
Number of subjects: 0
Study 26585432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary exacerbation score and lung function assessment
Number of subjects: 0
Study 26585432 — intervention group
Group type: COMPARATOR
Intervention: Assessment of bacterial density
Number of subjects: 0
Study 26585432 — intervention group
Group type: COMPARATOR
Intervention: Absolute neutrophil counts
Number of subjects: 0
Study 26585432 — intervention group
Group type: COMPARATOR
Intervention: Sputum inflammatory markers
Number of subjects: 0
Study 26585508 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE CMR examination
Number of subjects: 235
Study 26585609 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 453
Study 26585609 — intervention group
Group type: EXPERIMENTAL
Intervention: Home stool test (HST)
Number of subjects: 453
Study 26585609 — intervention group
Group type: COMPARATOR
Intervention: Overall CRC screening uptake
Number of subjects: 453
Study 26586415 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI MATCH trial intervention (molecular analysis for therapy choice)
Number of subjects: 0
Study 26586418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit physical activity tracker and website intervention for 16 weeks
Number of subjects: 25
Study 26587282 — intervention group
Group type: EXPERIMENTAL
Intervention: iStent implantation and cataract surgery (combined group)
Number of subjects: 36
Study 26587282 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery alone (control group)
Number of subjects: 36
Study 26587949 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending radiologists
Number of subjects: 199
Study 26587949 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior residents
Number of subjects: 199
Study 26587949 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd-year residents
Number of subjects: 199
Study 26587949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st-year residents
Number of subjects: 199
Study 26588924 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib 420 mg
Number of subjects: 15
Study 26588924 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib 560 mg
Number of subjects: 15
Study 26588924 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib 140 mg and 280 mg (single-dose phase)
Number of subjects: 15
Study 26588924 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib 420 mg (multiple-dose phase)
Number of subjects: 15
Study 26589752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of allogeneic mesenchymal stromal cells (MSCs) at a median dose of 2.7 × 10(6) cells/kg/infusion, range 1.3-4.5, given weekly for 2 to 5 weeks, in addition to standard rabbit ATG and cyclosporine.
Number of subjects: 9
Study 26589752 — intervention group
Group type: COMPARATOR
Intervention: Standard rabbit ATG and cyclosporine (control group).
Number of subjects: 9
Study 26589907 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated transpulmonary gradient
Number of subjects: 0
Study 26589907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance-derived right ventricular remodeling
Number of subjects: 0
Study 26589963 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab treatment in SJIA patients
Number of subjects: 0
Study 26589963 — intervention group
Group type: COMPARATOR
Intervention: Active AOSD prior to canakinumab treatment
Number of subjects: 0
Study 26589963 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study 26590174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous abatacept (∼10 mg/kg) plus MTX for 24 weeks
Number of subjects: 89
Study 26590194 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk factors (SNPs) related to BMP7 (rs75161997)
Number of subjects: 899
Study 26590194 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk factors (SNPs) related to PROX1-AS1 (rs1891059)
Number of subjects: 899
Study 26590194 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk factors (SNPs) related to GRID2 (rs34144324)
Number of subjects: 899
Study 26590194 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of BMP7 and PROX1-AS1 variants (rs75161997 and rs1891059)
Number of subjects: 899
Study 26590773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal microbiota influence
Number of subjects: 0
Study 26590912 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 448
Study 26590912 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 448
Study 26590963 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic endovascular aortic repair (TEVAR) with left subclavian artery coverage
Number of subjects: 11
Study 26590963 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR
Number of subjects: 11
Study 26593973 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33 ± 1 °C)
Number of subjects: 22
Study 26593973 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (48 hours after hypothermia)
Number of subjects: 22
Study 26593973 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 22
Study 26593973 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia and normothermia
Number of subjects: 22
Study 26595305 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 28
Study 26595305 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 26595440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-eat cereal (RTEC) consumers
Number of subjects: 367442
Study 26595440 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fiber intake among RTEC consumers
Number of subjects: 367442
Study 26595450 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug regimen (ledipasvir, sofosbuvir, GS-9451) for 4 weeks
Number of subjects: 50
Study 26595450 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen (ledipasvir, sofosbuvir, GS-9451, GS-9669) for 4 weeks
Number of subjects: 50
Study 26595611 — intervention group
Group type: COMPARATOR
Intervention: Lactation intensity (exclusive lactation, mostly lactation, mostly formula or mixed/inconsistent)
Number of subjects: 1035
Study 26595611 — intervention group
Group type: COMPARATOR
Intervention: Lactation duration (greater than 0 to 2 months, greater than 2 to 5 months, greater than 5 to 10 months, greater than 10 months)
Number of subjects: 1035
Study 26596767 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated volumetric segmentation tools
Number of subjects: 21
Study 26596767 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation by neuroradiologist and general radiologist
Number of subjects: 21
Study 26596767 — intervention group
Group type: EXPERIMENTAL
Intervention: Exportation of data
Number of subjects: 21
Study 26596948 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D regimen (ombitasvir-paritaprevir-ritonavir) with sofosbuvir
Number of subjects: 32
Study 26596948 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D regimen (ombitasvir-paritaprevir-ritonavir) with sofosbuvir
Number of subjects: 32
Study 26596948 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir alone
Number of subjects: 32
Study 26597091 — intervention group
Group type: EXPERIMENTAL
Intervention: MeTree web-based health risk assessment tool
Number of subjects: 20